Literature DB >> 16404500

Prolactinoma and systemic lupus erythematosus: do serum prolactin levels matter?

Margaret Li1, Harold D Keiser, Elena Peeva.   

Abstract

The lactogenic hormone prolactin is produced in part by cells of the immune system and serves as an upregulator of immune function. Hyperprolactinemia is common in patients with systemic lupus erythematosus (SLE), raising the possibility that the hormone contributes to the excessive immune response in the disease. The highest levels of circulating prolactin occur in association with prolactin-secreting tumors, but prolactinomas have only rarely been encountered in patients with SLE. We present here three patients with SLE and prolactinomas. As with the previously reported six patients, there was no consistency in the presence of findings related to prolactin excess or in the coincidence of hyperprolactinemia with flares of SLE disease activity. We speculate that this may be due to genetic differences in the response to prolactin and/or to the presence of variant prolactin isoforms detected in the clinical immunoassay that have reduced or absent biologic activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16404500     DOI: 10.1007/s10067-005-0117-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  14 in total

Review 1.  The role of sex hormones in systemic lupus erythematosus.

Authors:  R G Lahita
Journal:  Curr Opin Rheumatol       Date:  1999-09       Impact factor: 5.006

2.  Biologic activity and plasma clearance of prolactin-IgG complex in patients with systemic lupus erythematosus.

Authors:  A Leaños-Miranda; K A Chávez-Rueda; F Blanco-Favela
Journal:  Arthritis Rheum       Date:  2001-04

3.  First reported pediatric case of systemic lupus erythematosus associated with prolactinoma.

Authors:  Peter D Reuman
Journal:  Arthritis Rheum       Date:  2004-11

Review 4.  Prolactin and neuroimmunomodulation: in vitro and in vivo observations.

Authors:  I C Chikanza
Journal:  Ann N Y Acad Sci       Date:  1999-06-22       Impact factor: 5.691

5.  Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.

Authors:  N Kanda; T Tsuchida; K Tamaki
Journal:  Arthritis Rheum       Date:  1999-02

6.  Hyperprolactinemia in asymptomatic patients is related to high molecular weight posttranslational variants or glycosylated forms.

Authors:  M Guitelman; M E Colombani-Vidal; C C Zylbersztein; L Fiszlejder; M Zeller; O Levalle; H E Scaglia
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

7.  Hyperprolactinemia in male NZB/NZW (B/W) F1 mice: accelerated autoimmune disease with normal circulating testosterone.

Authors:  R McMurray; D Keisler; S Izui; S E Walker
Journal:  Clin Immunol Immunopathol       Date:  1994-06

Review 8.  Prolactin as a modulator of B cell function: implications for SLE.

Authors:  Elena Peeva; Jeganathan Venkatesh; Daniel Michael; Betty Diamond
Journal:  Biomed Pharmacother       Date:  2004-06       Impact factor: 6.529

9.  Prolactin influences autoimmune disease activity in the female B/W mouse.

Authors:  R McMurray; D Keisler; K Kanuckel; S Izui; S E Walker
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

10.  Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus.

Authors:  R W McMurray; D Weidensaul; S H Allen; S E Walker
Journal:  J Rheumatol       Date:  1995-11       Impact factor: 4.666

View more
  2 in total

Review 1.  The role of the prolactin/vasoinhibin axis in rheumatoid arthritis: an integrative overview.

Authors:  Carmen Clapp; Norma Adán; María G Ledesma-Colunga; Mariana Solís-Gutiérrez; Jakob Triebel; Gonzalo Martínez de la Escalera
Journal:  Cell Mol Life Sci       Date:  2016-03-29       Impact factor: 9.261

Review 2.  Prolactin and autoimmunity.

Authors:  Luis J Jara; Gabriela Medina; Miguel A Saavedra; Olga Vera-Lastra; Carmen Navarro
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.